hide
Free keywords:
LIPOMA-PREFERRED-PARTNER; NF-KAPPA-B; LIM PROTEIN; HEART-FAILURE;
TARGETED DISRUPTION; GENE; HYPERTROPHY; ASSOCIATION; ACTIVATION; ZYXINMigfilin; Cardiac hypertrophy; Cardiac function; Pressure overload;
Myocardial remodelling;
Abstract:
Aims Increased myocardial wall strain triggers the cardiac hypertrophic response by increasing cardiomyocyte size, reprogramming gene expression, and enhancing contractile protein synthesis. The LIM protein, migfilin, is a cytoskeleton-associated protein that was found to translocate in vitro into the nucleus in a Ca2+-dependent manner, where it co-activates the pivotal cardiac transcription factor Csx/Nkx2.5. However, the in vivo role of migfilin in cardiac function and stress response is unclear.
Methods and results To define the role of migfilin in cardiac hypertrophy, we induced hypertension by transverse aortic constriction (TAC) and compared cardiac morphology and function of migfilin knockout (KO) with wild-type (WT) hearts. Heart size and myocardial contractility were comparable in untreated migfilin KO and WT hearts, but migfilin-null hearts presented a reduced extent of hypertrophic remodelling in response to chronic hypertensile stress. Migfilin KO mice maintained their cardiac function for a longer time period compared with WT mice, which presented extensive fibrosis and death due to heart failure. Migfilin translocated into the nucleus of TAC-treated cardiomyocytes, and migfilin KO hearts showed reduced Akt activation during the early response to pressure overload.
Conclusions Our findings indicate an important role of migfilin in the regulation of cardiac hypertrophy upon experimental TAC.
